Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TG Therapeutics's change in inventory for the quarter that ended in Jun. 2026 was €-58.0 Mil. It means TG Therapeutics's inventory
increased by €58.0 Mil
from Mar. 2026 to Jun. 2026 .
TG Therapeutics's change in inventory for the fiscal year that ended in Dec. 2025 was €-28.6 Mil. It means TG Therapeutics's inventory
increased by €28.6 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
TG Therapeutics's Days Inventory for the quarter that ended in Jun. 2026 was 306.30.
Inventory Turnover measures how fast the company turns over its inventory within a year.
TG Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.30.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
TG Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.58.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
TG Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TG Therapeutics Change In Inventory Related Terms
TG Therapeutics Change In Inventory Historical Data
* Premium members only.
The historical data trend for TG Therapeutics's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-61.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of €-61.6 Mil mean?
TG Therapeutics (FRA:NKB2) has a Change In Inventory of €-61.6 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for TG Therapeutics and its competitors.
Is TG Therapeutics' Change In Inventory too high?
TG Therapeutics' current Change In Inventory is €-61.6 Mil. Overall, TG Therapeutics has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' Change In Inventory compare to PTGX and CRNX?
TG Therapeutics' Change In Inventory of €-61.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for TG Therapeutics and its competitors. TG Therapeutics's current Change In Inventory is €-61.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
TG Therapeutics (FRA:NKB2) has a current Change In Inventory of €-61.6 Mil. The current Change In Inventory is €-61.6 Mil. TG Therapeutics' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For TG Therapeutics (FRA:NKB2), the current Change In Inventory is €-61.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
60GF Score
Get the complete analysis for FRA:NKB2
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NKB2 has been successfully added to your 
